TuHURA Biosciences Inc (HURA) Stock Forecast
HURA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 4 analysts
- Price target
- $8.04 average of analyst targets
- Upside to target
- +356.8% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.14
- 52-week range
- $0.44 – $3.15
HURA analyst ratings
4 analystsNumber of analysts at each rating.
HURA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
HURA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.13 | −$0.14 | −$0.12 | −$0.14 | +7.1% | 2 |
| Current fiscal year (FY2026) | −$0.53 | −$0.55 | −$0.51 | −$0.66 | +19.3% | 2 |
| Next fiscal year (FY2027) | −$0.60 | −$0.61 | −$0.60 | −$0.53 | −14.1% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
HURA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 5 |
| Current fiscal year (FY2026) | $0 | $0 | $0 | 0.0% | 5 |
| Next fiscal year (FY2027) | $13.5M | $0 | $67.7M | 0.0% | 5 |
HURA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
HURA revenue: reported and forecast
HURA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.13 | −$0.13 | −$0.13 | $0.00 | −$0.13 | 0.0% | 1 up · 0 down |
| Current fiscal year (FY2026) | −$0.50 | −$0.50 | −$0.50 | $0.00 | −$0.53 | +6.0% | 1 up · 0 down |
| Next fiscal year (FY2027) | $0.00 | $0.00 | $0.00 | $0.00 | −$0.60 | — | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
HURA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; HURA beat in 3 of 9.
What analysts expect from HURA
4 analysts cover TuHURA Biosciences; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $8.04, 356.8% above the latest close of $1.76. Analysts expect earnings of −$0.53 per share for FY2026, +19.3% from a year earlier. For FY2027 the average estimate is −$0.60 per share on revenue of $13.5 million. TuHURA Biosciences beat the EPS estimate in 3 of the last 9 quarters.
Related: HURA income statement, HURA key metrics, HURA chart. See the HURA stock overview for the latest quote and news.
HURA forecast FAQ
What is TuHURA Biosciences's price target?
The average analyst price target for TuHURA Biosciences is $8.04, 356.8% above the latest close of $1.76.
Is TuHURA Biosciences a buy, hold or sell?
Of 4 analysts covering TuHURA Biosciences, 2 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is TuHURA Biosciences's EPS forecast?
Analysts forecast −$0.53 per share for FY2026 (range −$0.55 to −$0.51); for FY2027 the estimate is −$0.60.
When does TuHURA Biosciences report earnings?
TuHURA Biosciences is expected to report results for the quarter ending September 30, 2026 on November 13, 2026 before the market opens; the EPS estimate is $-0.14.
Does TuHURA Biosciences usually beat earnings estimates?
TuHURA Biosciences reported EPS at or above the analyst estimate in 3 of the last 9 quarters.